These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6726304)

  • 1. Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma.
    King ME; Pfeifle CE; Howell SB
    J Clin Oncol; 1984 Jun; 2(6):662-9. PubMed ID: 6726304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extremely prolonged continuous intraperitoneal infusion of cytosine arabinoside.
    Kirmani S; Zimm S; Cleary SM; Mowry J; Howell SB
    Cancer Chemother Pharmacol; 1990; 25(6):454-8. PubMed ID: 2311175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal cytosine arabinoside administered in sequence with systemic cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Campora E; Bruzzone M; Chiara S; Alama A; Iskra L; Carnino F; Parodi S; Foglia G; Ragni N; Rosso R
    Gynecol Oncol; 1990 Apr; 37(1):39-43. PubMed ID: 2323610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia.
    Yang JL; Cheng EH; Capizzi RL; Cheng YC; Kute T
    J Clin Invest; 1985 Jan; 75(1):141-6. PubMed ID: 4038404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine after intraperitoneal administration].
    Noda T; Oku M; Kiyozuka Y; Maruyama M; Adachi S; Akada S; Okamura Y; Ichijo M
    Gan To Kagaku Ryoho; 1988 Oct; 15(10):2929-35. PubMed ID: 3178241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytosine arabinoside cerebrospinal fluid kinetics.
    Zimm S; Collins JM; Miser J; Chatterji D; Poplack DG
    Clin Pharmacol Ther; 1984 Jun; 35(6):826-30. PubMed ID: 6587957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides.
    Sinkule JA; Evans WE
    J Chromatogr; 1983 May; 274():87-93. PubMed ID: 6575975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
    Dedrick RL; Myers CE; Bungay PM; DeVita VT
    Cancer Treat Rep; 1978 Jan; 62(1):1-11. PubMed ID: 626987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity.
    Markman M; Cleary S; Lucas WE; Howell SB
    J Clin Oncol; 1985 Jul; 3(7):925-31. PubMed ID: 3894586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity.
    Markman M; Howell SB; Lucas WE; Pfeifle CE; Green MR
    J Clin Oncol; 1984 Dec; 2(12):1321-6. PubMed ID: 6542584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.
    Markman M; Hakes T; Reichman B; Hoskins W; Rubin S; Jones W; Almadrones L; Yordan EL; Eriksson J; Lewis JL
    J Clin Oncol; 1991 Feb; 9(2):204-10. PubMed ID: 1988569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI; Powell W
    Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of prolonged-release derivative of cytosine arabinoside, cytosine arabinoside-agarose conjugate.
    Hashida M; Kojima T; Muranishi S; Sezaki H
    Gan; 1978 Dec; 69(6):839-43. PubMed ID: 750275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.
    Esteva FJ; Soh LT; Holmes FA; Plunkett W; Meyers CA; Forman AD; Hortobagyi GN
    Cancer Chemother Pharmacol; 2000; 46(5):382-6. PubMed ID: 11127942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effects of cis-platinum and cytosine arabinoside on ovarian carcinoma cell lines, demonstrated by dual-parameter flow cytometry.
    Kingston RE; Sevin BU; Ramos R; Saks M; Donato D; Jarrell MA; Averette HE
    Gynecol Oncol; 1989 Mar; 32(3):282-7. PubMed ID: 2920948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of combined intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian cancer model.
    Berek JS; Schink JC; Knox RM
    Obstet Gynecol; 1989 Oct; 74(4):663-6. PubMed ID: 2797645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
    Kreis W; Hession C; Soricelli A; Scully K
    Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma.
    D'Acquisto R; Markman M; Hakes T; Rubin S; Hoskins W; Lewis JL
    J Clin Oncol; 1988 Apr; 6(4):689-95. PubMed ID: 3128649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer.
    Markman M; Hakes T; Reichman B; Lewis JL; Rubin S; Jones W; Almadrones L; Hoskins W
    J Clin Oncol; 1991 Jun; 9(6):978-82. PubMed ID: 2033432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.